. The Angiogenic Switch Occurs Prior to Tumor Formation in Three Transgenic Mouse Models of Tumorigenesis (A) Expression of the Tag oncogene in the pancreatic islets elicits four sequential stages in tumor development: normal, oncogene-expressing islets; hyperplastic islets, populated by proliferating cells with the histological hallmarks of CIS; angiogenic islets, in which new blood vessel growth has been activated; and solid tumors, which are islet cell carcinomas. (B) In transgenic mice carrying the BPV-1 oncogenes, the normal dermis is initially converted into a state of mild fibromatosis, revealed as focal accumulation of dermal fibroblasts. Angiogenesis is first evident in the next stage, aggressive fibromatosis, which is also marked by dense arrays of proliferating fibroblastic cells; both hyperproliferation and angiogenesis persist in the subsequent stage, protuberant fibrosarcoma. (C) Targeted expression of the HPV-16 oncogenes to basal cells of the epidermis induces multistage development of squamous cell carcinoma, beginning as hyperplasia of keratinocytes, with a mild increase in vessel density; which progresses to dysplasia, marked by morphologically aberrant keratinocytes with a high proliferation index and by abundant neovascularization; finally, two classes of squamous carcinoma arise, both evidencing extensive angiogenesis.
carcinoma, dermal fibrosarcoma, and epidermal squa-12-16 weeks of age. The distribution of this cell type into these natural focal nodules has allowed histological, mous cell carcinoma. In all three models, extensive vascularization and ongoing angiogenesis has been appartemporal, and statistical analysis of tumorigenesis. A set of four discrete stages in the pathway to cancer is ent in the end-stage tumors. Remarkably, in each case, an angiogenic switch could also be visualized during apparent by these criteria. Initially, every islet contains ␤ cells, which express the oncogene but otherwise appear early stages preceding the appearance of the solid tumors, suggesting that activation of angiogenesis is a normal, with a low proliferation index. Then, focal activation of hyperproliferation occurs in individual islets discrete event in tumor development. These models are summarized briefly, in turn; the results are schematized (Teitelman et al., 1988) . This stage, while historically referred to as "hyperplastic," is composed of cells with in Figure 1 .
The so-called "RIP-Tag" transgenic mice express the the histological properties of a carcinoma-in-situ (CIS), wherein more than 20% of the cells are in S phase SV40 T antigen (or Tag) oncogene in the insulin-producing ␤ cells (Hanahan, 1985) , which are localized in apat any given time. Insulin-like growth factor (IGF)-II is activated at this stage and probably modulates proximately 400 islet nodules scattered throughout the pancreas. In several independent lines of mice, a few apoptosis that accompanies the aberrant proliferation (Christofori et al., 1994 (Christofori et al., , 1995a Naik et al., 1994 ). Yet, (2-10) of these 400 islets develop into solid tumors by these hyperplastic islet nodules, while morphologically important test of the value of mouse models is the applicability of observations made therein to the human transformed in appearance, are not competent to proceed directly to a rapidly growing islet cell carcinoma, condition. In two case studies, angiogenesis has been detected in preneoplastic stages, consistent with identisince 50% of the islets switch to the hyperproliferative (CIS) stage, while only 1%-2% progress to solid tumors.
fication of the angiogenic switch as a step in the pathway to human cancer, as the following section elaborates. We have identified a discrete stage, referred to as "angiogenic islet," that appears to be an intermediate between these two stages, both statistically and tempoAngiogenesis in Premalignant Stages rally. We defined the angiogenic switch using an in vitro of Two Human Cancers bioassay for angiogenic activity, in which capillary endoThe use of immunological markers to visualize the vasthelial cells were cocultured in a three-dimensional colculature has become an important new tool in assessing lagen gel with islets isolated at different ages from the the histopathology of cancerous lesions, as seen for RIP-Tag mice (Folkman et al., 1989) . At early ages, none example in the murine fibrosarcoma study discussed of the oncogene-expressing islets were angiogenic.
above (Kandel et al., 1991) . Both von Willebrand's factor Then, in older mice, individual islets scored as angio-(vWF) and CD31 are expressed widely, albeit variably, genic, attracting a starburst of endothelial cells convergin the endothelium, which has allowed these and other ing on the angiogenic islet. Over time, about 10% of the markers to be used as tools to assess the density and total islets scored as angiogenic. The in vitro bioassay character of capillaries in tissue sections. In human onwas substantiated by histological analysis, which recology, an important application of this capability to vealed two hallmarks of angiogenesis, capillary sproutvisualize capillaries has been the development of new ing and endothelial cell proliferation, in a subset of the prognostic tests for probability of relapse (or diseasehyperplastic islets and in all solid tumors in these free survival) following surgical resection of an invasive transgenic mice (Folkman et al., 1989) . The provocative cancer. Vessel density in invasive cancers has been result was that neither oncogene expression nor hyperdemonstrated to be a significant prognostic indicator, proliferation appeared to be sufficient to activate the both for breast (Weidner et al., 1991) and prostate angiogenic switch, which rather appeared as a discrete, (Weidner et al., 1993) cancers; if the vessel density was temporally separate step in this multistage pathway (Fig- low, the prognosis was good, whereas the prognosis ure 1A).
fell with increasing density of blood vessels, the mark of A second transgenic mouse model of multistage tua potent angiogenic response. In addition to evaluating morigenesis, in which the bovine papillomavirus oncomalignant carcinomas, immunostaining with endothelial genes elicit dermal fibrosarcomas (Lacey et al., 1986;  cell markers has been used to detect angiogenesis in Sippola-Thiele et al., 1988) , has also been analyzed for preneoplastic lesions associated with cancers of the the appearance of angiogenesis (Kandel et al., 1991) . mammary duct and the uterine cervix. The results are Dense vascularization and evidence of new blood vessel schematized in Figure 2 . Briefly, histopathological evalugrowth first became apparent in a late preneoplastic ation of biopsies taken from cancerous breasts has restage, aggressive fibromatosis; angiogenesis was also vealed distinctive preneoplastic lesions, including hyevident in all end-stage fibrosarcomas ( Figure 1B) . Even perplastic ducts, dysplastic ducts, and CIS. Using vWF though the fibrosarcoma model is very different from immunostaining, a subset of the CIS lesions in the huthe islet cell system, the results suggest again that angiman breast can be seen to be angiogenic (Brown et al., ogenesis is a rate-limiting step in tumor development. 1995; Guidi et al., 1994; Weidner et al., 1992) , in loose Moreover, the pattern persisted when a third transgenic analogy to the subset of hyperproliferative ("CIS-like") model was investigated, wherein basal keratinocytes islets in the RIP-Tag mice that are angiogenic. In conwere progressively transformed into squamous cell cartrast to the mouse, it has not been possible to perform cinomas by the human papillomavirus type 16 oncocomprehensive temporal and histological analyses on genes (Arbeit et al., 1994 (Arbeit et al., , 1996 Arbeit, 1996;  Coussens the early development of these presumptive stages in et al., Hurlin et al., 1995) . Here again, the angiothe human breast, but the patterns are remarkably simigenic switch was evident prior to the emergence of the lar. Thus, we infer that angiogenic CIS lesions in the squamous cancers ( Figure 1C) . In this multistage model breast may represent an intermediate stage that sepaof squamous carcinogenesis, weak angiogenic activity rates preangiogenic CIS and invasive cancer. could be detected in the hyperplastic stage in the form
The human cervix has been extensively characterized of modestly increased vessel density in the underlying through the routine collection of PAP smears, which dermis. Angiogenesis became pronounced in the dyshas revealed a series of aberrant proliferative stages, plastic stage, with abundant capillaries juxtaposed to ranging from varying grades of dysplasia to CIS (histothe basement membrane separating stroma from dyslogically graded as CIN I-III) and invasive cancer; about plastic cells. Intense vascularization persisted in the in-80% of cervical carcinomas contain fragments of an vasive squamous cancers that arose out of such dys-HPV genome (typically HPV16/18) and express viral onplastic lesions (Smith-McCune et al., submitted) .
cogenes. When biopsies of cervical lesions were anaIn summary, all three of the diverse transgenic mouse lyzed by immunostaining with vWF to reveal the capillarmodels of tumorigenesis analyzed to date have revealed ies, an angiogenic switch was readily apparent in the an angiogenic switch that becomes activated during mid-late dysplasias (CIN II-III), wherein new vessels bethe early stages of tumor development, suggesting that came densely apposed along the basement membrane regulation of angiogenesis is a discrete, potentially ratelimiting step in the pathway to many solid tumors. One underlying the dysplastic epithelium (Guidi et al., 1995; Smith- McCune and Weidner, 1994 ). An initial mild inTherefore, having argued that regulation of the switch crease in vessel density has been detected in the early is important and potentially rate-limiting for initial tumor dysplastic (CIN I) stage (Guidi et al., 1995; Smith- development as well as for the expansion and metastaMcCune et al., submitted). This pattern is remarkably sis of an established tumor, we now wish to discuss the similar to that seen in the epidermis of K14-HPV16 emerging picture of how the angiogenic switch may be transgenic mice, which presents a similar multistage controlled. pathway in another squamous epithelium (of the skin) under the influence of the HPV16 oncogenes. Thus, we Emerging Mechanisms of the Angiogenic Switch infer that the angiogenic switch is a very early event in
The Angiogenic Inducers the pathways to invasive squamous cell cancers, per-
The observation that tumors could be implanted either haps occurring in two regulatory phases, of mild and into an avascular region, such as the cornea, or on a intense neovascularization. Clues from cell culture biocharacteristically vascularized surface, such as the assays also support this notion that the switch can have chick chorioalantoic membrane, and in each case elicit several "on" settings, which progressively ratchet up the ingrowth of new capillaries, suggested that tumors the intensity of neovascularization.
released diffusible activators of angiogenesis that could The pattern of new blood vessel growth, described signal a quiescent vasculature to begin capillary sprouthere in five cancers spanning two species and five cell ing. This hypothesis motivated a search for so-called types, argues, first, that the angiogenic switch is a distumor angiogenesis factors. Indeed, inducers of angiocrete process, subject to specific regulatory controls; genesis have been identified. A number of in vitro and and second, that the switch is an essential part of the in vivo bioassays have been developed to mimic the phenotypic repertoire that characterizes a successful complex process of angiogenesis (reviewed by Cockerill tumor. Figure 3 presents a histological picture of the et al., 1995). Among these, two assays in particular have angiogenic switch in these five models. A similar stagebeen widely used to screen for angiogenic regulatory specific switch is evident during development of cutaneous melanoma in humans (reviewed by Rak et al., 1995) .
factors, each mimicking an aspect of angiogenesis; The human breast panels show a CIS (left), with normal duct-associated vasculature, and an angiogenic-CIS lesion (right), with extensive neovascularization. The mouse dermis panels show a prevascular mild fibromatosis lesion (left), with a few vessels deep in the dermis, and an aggressive fibromatosis (right), with large capillaries spread throughout the thickened dermal layer. In the human cervix, a normal tissue (left) has vessels deep in the stroma, whereas the CIN III lesion (right) has attracted a dense array of new capillaries underlying the basement membrane. In the normal mouse ear, a few vessels are present in the stroma (left), whereas in HPV-16-induced epidermal dysplasia, capillaries are distributed throughout the dermis, in particular closely juxtaposed to the basement membrane underlying the transformed keratinocytes. The islet panels were stained with hematoxylin and eosin, while the remainder were first immunostained with antisera to the blood vessel marker vWF and then counterstained with hematoxylin alone or with hematoxylin and eosin (mouse dermis). All magnifications are approximately 62ϫ.
namely, endothelial cell proliferation and migration. The same time, a secreted protein was identified by its ability to elicit vascular permeability (Senger et al., 1983) ; subproliferation assay uses cultured capillary endothelial cells and measures either increased cell number or the sequently, this factor, called vascular permeability factor or vascular endothelial growth factor (VPF/VEGF), incorporation of radiolabeled or modified nucleosides to detect cells in S phase. In contrast, the chemotaxis was shown to be a potent inducer of angiogenesis (reviewed by Brown et al., 1996; Ferrara, 1993) . Recently, assay separates endothelial cells and a test solution by a porous membrane disc (a Boyden Chamber), such two related endothelial growth factors, VEGF-B and VEGF-C, have been identified (Olofsson et al., 1996 ; that migration of endothelial cells across the barrier is indicative of a chemoattractant present in the test soluJoukov et al., 1996; Lee et al., 1996; Grimmond et al., 1996) . All three VEGF genes as well as acidic and basic tion. Both assays have inherent strengths, biases, and limitations; each is often complemented by the use of FGF are widely expressed in normal adult organs of mice and humans, suggestive of roles in tissue homeoan in vivo assay, such as implants into the normally avascular cornea of rabbits or rodents (the "corneal stasis as well as angiogenesis, since the later is such a rare event in most tissues. Both a/bFGF and VEGF bind pocket" assay). A number of inducers of angiogenesis have been detected using these assays. The first to be to receptors on endothelial cells that are transmembrane tyrosine kinases and thus are coupled through the signal discovered (in 1982) was basic fibroblast growth factor (bFGF, or FGF-2), followed shortly by its relative, acidic transduction cascade to the cellular regulatory network. The three VEGF receptors, flk, flt-1, and flt-4 (VEGFR-FGF (aFGF, or FGF-1; reviewed by Friesel and Maciag, 1995; Folkman and Shing, 1992) .
1-3), are specifically expressed on endothelial cells (reviewed by Brown et al., 1996; Risau and Flamme, 1995) , Both proteins are members of a family of growth factors that are characterized by high affinity binding to heparin; whereas the four FGF receptors, FGFR1-4, are more widely expressed (reviewed by Christofori, 1996; Friesel each is unusual in its lack of a traditional signal sequence for secretion. Both, however, can be released from cells and Maciag, 1995; Rak et al., 1995) . During the past decade, an increasing number of angiunder certain circumstances Friesel and Maciag, 1995; Kandel et al., 1991) . At about the ogenic inducers has been identified (reviewed by Bouck et al., 1996; Folkman, 1995a Folkman, , 1995b . Concurrently, howas astrocytes (Van Meir et al., 1994) , to control angiogenesis-inhibitory activities distinct from TSP. The bottom ever, a pattern has emerged, in that bFGF and VEGF are commonly expressed in a wide variety of human line of these experiments is, first, that endogenous angiogenesis inhibitors can serve to counteract inducer sigand animal cancers; moreover, bFGF (and now VEGF) is being detected at elevated levels in the urine and nals to grow new capillaries; and second, that these angiogenesis inhibitors can be controlled by tumor supserum of a significant fraction of tumor-bearing patients (as discussed in Folkman, 1995a Folkman, , 1995b . Interestingly, pressor genes, consistent with the functional definition of such genes as interfering with the tumor phenotype, VEGF and bFGF have been shown to synergize using in vitro angiogenesis assays (Pepper et al., 1992 ; Goto et of which angiogenesis is a key component. al., 1993) , indicating that they can serve complementary functions, consistent with their common association in
A New Paradigm of Cryptic Angiogenesis

Inhibitors within Larger Proteins
The fact that the endothelium is quiescent for long peritumors. Indeed, the tumor development pathways of all three transgenic mouse models presented in Figure 1 ods and yet can be induced to sprout new capillaries in a matter of hours in response to, for example, a evidence an involvement of VEGF and either aFGF, bFGF, or both. Thus, these two classes of angiogenic wound, has long suggested that angiogenesis regulators might be stored for expedient use. In addition, one inducer certainly represent a frequent component of the angiogenic switch. Notwithstanding this consensus, the can expect that regulators will be synthesized for persistence of an angiogenic response. It is known that the diversity and number of angiogenic inducers identified to date argues that there will also prove to be tissueFGFs and other growth and angiogenic factors can be sequestered in the extracellular matrix of many cell specific and perhaps transformation-specific regulators associated with particular cancers and with the normal types, including endothelial cells, presumably to be released by proteolytic degradation of the matrix (Baird physiological regulation of angiogenesis. Moreover, convergent on this perspective regarding angiogenic and Ling, 1987; Folkman et al., 1988) . It now appears that angiogenesis inhibitors are also stored, but in a inducers has been the realization that there is an equally important component to the switch, one governed by much different fashion, as cryptic parts of larger molecules that are not themselves inhibitors of angiogenesis. negative regulatory factors, called angiogenesis inhibitors.
The prototype came from the discovery that a 29 kDa fragment of fibronectin inhibited endothelial cell proliferThe Angiogenic Inhibitors The first clues to the existence of endogenous angiogenation in vitro (Homandberg et al., 1985) . Notably, the intact fibronectin molecule, an abundant component of esis inhibitors came with the observations that ␣ interferon (Brouty-Boye and Zetter, 1980; Sidky and Borden, the circulatory system, was not itself an inhibitor. Subsequently, a fragment of prolactin, the 16 kDa fragment, 1987) and platelet factor-4 (Taylor and Folkman, 1982; Sato et al., 1990; Sharp et al., 1990 ) could inhibit endowas shown to be an inhibitor of endothelial cells, whereas the intact molecule was not (Clapp et al., 1993; thelial cell chemotaxis and proliferation, respectively. But the significance of negative regulators of angiogenFerrera et al., 1991). More recently, a potent inhibitor of angiogenesis, called angiostatin, has been identified as esis first became apparent through a series of experiments by Bouck and colleagues (Good et al., 1990 ; Rasa fragment of plasminogen . Circulating angiostatin is able to maintain the dormancy of tinejad et al., 1989). A nontumorigenic hamster cell line became tumorigenic concomitant with a mutation that metastases and primary tumors by blocking blood vessel growth, resulting in small nests of tumor cells that inactivated a tumor suppressor gene. Comparison of cell lines containing or missing the suppressor gene cycle through proliferation and apoptosis, restrained by their inability to induce angiogenesis to support their revealed that the nontumorigenic line released high levels of a potent angiogenesis inhibitor, both of endothelial growth O'Reilly et al., 1994 O'Reilly et al., , 1996 . The fact that abundant components of the circulatory chemotaxis in the Boyden Chamber assay and of in vivo neovascularization using the corneal pocket assay; by system such as fibronectin and plasminogen can be converted into potent angiogenic factors suggests a comparison, the tumorigenic cell lines had much lower levels of inhibitor (Rastinejad et al., 1989) . The inhibitory new form of regulation, whereby proteases specifically release 29 kDa fibronectin or angiostatin from their intact activity was purified and shown to be a truncated form of thrombospondin-1 (TSP-1), a secreted glycoprotein. parental molecules to limit an angiogenic response, for example in the transient wound healing process. ReSubsequently, the intact TSP-1 molecule was shown to be an angiogenesis inhibitor (Good et al., 1990) , as were cently, platelet factor-4, itself a weak angiogenesis inhibitor, has been shown to contain a fragment that is small peptides contained within it (Tolsma et al., 1993) . Further, TSP-1 has been shown to be expressed at high 50 times more potent at inhibiting angiogenesis (Gupta et al., 1995) . The pattern of protease fragments as angiolevels in a number of normal rodent and human cells and at appreciably lower levels in many tumor cells.
genesis inhibitors continues to expand to other molecules, including the propeptides of type 1 collagen (TolProvocatively, TSP-1 has recently been shown to be regulated by the wild-type p53 tumor suppressor protein sma et al., 1993) and a peptide fragment of epidermal growth factor (Nelson et al., 1995) . in fibroblasts (Dameron et al., 1994) and mammary epithelial cells (Volpert et al., 1995) , such that upon loss of Thus, a paradigm is emerging which suggests that a class of angiogenesis inhibitors is contained within other p53 function in their transformed derivatives, the levels of this angiogenesis inhibitor dropped precipitously.
proteins that are not themselves inhibitors. The capability to release inhibitor fragments from storage as cryptic Restoration of p53 function upregulated TSP-1 and impaired the angiogenic capability of the tumor cells. Fursegments of abundant proteins may contribute to maintaining the normal quiescence of the vasculature and thermore, p53 has been shown in other cell types, such The normally quiescent vasculature can be activated to sprout new capillaries (angiogenesis), a morphogenic process controlled by an angiogenic switch mechanism. The prevailing evidence suggests that changes in the relative balance of inducers and inhibitors of angiogenesis can activate the switch. In some tissues, the absence of angiogenesis inducers may keep the switch off, while in others the angiogenesis inducers are present but held in check by higher levels of angiogenesis inhibitors. Thus, either reducing the inhibitor concentration, e.g., for TSP-1, by loss of a tumor suppressor gene; or increasing the activator levels, e.g., for induction of VEGF, by hypoxia, can each change the balance and activate the switch, leading to the growth of new blood vessels.
to turning off transitory angiogenic processes such as 1989). The second clue comes from studying human tumor cells, in which the restoration of p53 tumor supovulation and wound healing; perhaps this strategy also serves the organism by suppressing tumorigenesis and pressor function results in up-regulation of TSP, overruling both the angiogenesis inducers that the cells themother diseases with an angiogenic component. A major question for the future relates to the source and regulaselves synthesize as well as added bFGF, thereby blocking angiogenesis (Dameron et al., 1994) . The third tion of the proteases that release the cryptic inhibitors. In one case, that of angiostatin, certain clones of Lewis clue comes from the pancreatic islet model for the angiogenic switch (see Figure 1) , in which two potent angiolung tumor paradoxically induce its release from circulating plasminogen . Beyond that, genic factors, aFGF and VEGF, are expressed consitutively in normal islet cells (of nontransgenic mice) as it is not clear what cell types normally serve to release cryptic inhibitors and under what circumstances. Eluciwell as throughout tumorigenesis in the transgenic mice Christofori et al., 1995b) . Remarkably, dation of mechanisms and regulation of cryptic angiogenic inhibitor release could well present therapeutic there is no new blood vessel growth in normal pancreatic islets, despite the expression of these potent angiogenopportunities. The Balance Hypothesis for the Angiogenic Switch esis inducers. It seems likely that angiogenesis inhibitors keep the switch off in normal islets expressing VEGF The above sections have summarized the evidence that angiogenesis can be regulated both by inducers and and aFGF. If so, then loss of these inhibitors would shift the balance and trigger the switch during tumorigenesis. inhibitors of endothelial cell proliferation and migration. But which class of angiogenic regulators is most imporIndeed, genetic evidence exists for an angiogenesis suppressor gene located on mouse chromosome 16; tant? Increasingly, there are provocative clues suggesting that the balance of inhibitors and inducers this locus frequently shows loss of heterozygosity both in the angiogenic islet stage and in end-stage tumors governs the angiogenic switch; the hypothesis is schematized in Figure 4 . A set of three clues summarizes of this tumorigenesis pathway . The predictions are, therefore, first, that an angiogenesis the basis for this hypothesis. The first clue comes from in vitro bioassays. In both proliferation and chemotaxis suppressor gene encodes or controls expression of an angiogenesis inhibitor that maintains the quiescence of assays, bFGF and VEGF can elicit a positive response from capillary endothelial cells. If increasing amounts the vasculature in normal islets constitutively expressing VEGF and aFGF; and second, that this angiogenic inhibiof an inhibitor such as TSP-1 are added, the response becomes blocked, suggesting that when the levels of tor is down-modulated during tumorigenesis, thus activating the angiogenic switch. inhibitors are sufficiently high, the signals of the positive activator(s) are overruled, keeping (or turning) the angioThese and other clues suggest a regulatory mechanism that integrates the cumulative levels of inducer genic switch off (Good et al., 1990; Rastinejad et al., and inhibitor signals to maintain the endothelial cell in Apoptosis, Clinical Applications, and the Goal to Control the Switch alternative states of quiescence or angiogenesis. Thus, The growing appreciation of the fact that angiogenesis changes in the balance of positive and negative signals is an integral component of the tumor phenotype has mediate the angiogenic switch (Figure 4) , a point Bouck fueled considerable efforts to identify angiogenesis inand colleagues have also made recently (Bouck et al., hibitors that can be used as part of therapeutic strate -1996) . A net balance of inhibitors over activators would gies to interfere with tumor growth and metastasis. In maintain the switch in the off position, whereas a shift addition to endogenous inhibitors such as interferon ␣/␤ to an excess of activating stimuli would turn on angioand platelet factor-4, synthetic compounds have been genesis. There are now ample tools to address this hyidentified using cell culture assays. These include the pothesis, and indeed, new observations seem likely to fungal-derived compound AGM1470 (TNP470), thalidorefine it. For example, aFGF and bFGF are selectively mide, a number of metalloproteinase inhibitors, and othexported by a number of tumor cell lines but not by ers (reviewed by Auerbach and Auerbach, 1994; Bouck many normal cells Friesel and Maciag, et al., 1996; Folkman, 1995a) . Currently, there are nine 1995; Kandel et al., 1991) , suggesting that another feacompounds in clinical trials as angiogenesis inhibitors, ture of the switch mechanism may be the capability with perhaps two dozen others in various stages of reto sequester angiogenesis inducers such that despite search and development as potential antiangiogenic being synthesized they are unavailable to stimulate angitherapeutics. ogenesis until the sequestration is relaxed. In regard to
Looking beyond this first generation of angiogenesis endogenous inhibitors, a major objective will be to asinhibitors identified in cell-based assays, we envision sess the proteolytic mechanisms and the generality by the capability to control the angiogenic switch through which cells can process abundant circulatory proteins specific knowledge both of the regulatory mechanism such as fibrinogen and plasminogen to release cryptic underlying the switch and the cellular details of the proangiogenesis inhibitors. Local processing of circulatory cess of new blood vessel morphogenesis. One approach proteins may serve to produce levels of inhibitory activwill likely involve altering the balance of endogenous ity sufficient to maintain the angiogenic switch in the off inhibitors and activators by controlling synthesis or afposition. If the endothelium is normally bathed in locally fecting sequestration and release. The beginnings of or systemically processed cryptic inhibitors, the regulathis approach are apparent. Monoclonal antibodies that tory balance could be shifted and the angiogenic switch bind and block the actions of VEGF are in development, activated either by reducing the rates of inhibitor proas are compounds that interfere with signal transduction cessing or by increasing the levels of the inducers seen from its receptors. Knowledge of the morphogenesis of at the endothelial cell, for example by up-regulating new vessels is also providing opportunities. For exam-VEGF synthesis or by releasing sequestered FGF. It ple, sprouting capillaries have been shown to express seems likely that the alternative strategies of increasing a specific type of cell-matrix interaction molecule, the activator levels or reducing inhibitor levels to activate integrins ␣ v␤3 or ␣v␤5; abrogation of the contacts of these the angiogenic switch will each be utilized by different integrins to matrix evokes programmed cell death (apoptosis) of the new endothelial cells and dramatically tissues according to their physiological characteristics.
impairs neovascularization of tumors (Brooks et al., Thus, tissues such as the epidermis, which are well 1994; Friedlander et al., 1995) . Both antiintegrin antibodseparated from the vasculature by a basement memies and interfering RDG peptides are in development brane and a stromal support, may favor mechanisms as candidates for blocking capillary morphogenesis via that increase inducer levels to elicit angiogenesis. In induction of apoptosis. contrast, endocrine organs such as the pancreatic islets One emerging biological principle is the interrelationthat are intimately vascularized may utilize negative regship between tumor angiogenesis and modulation of ulators to maintain a quiescent endothelium and therecell death. Classically, it has been apparent in certain fore require down-regulation of inhibitor production to tumors that necrotic death accompanies inadequate activate the angiogenic switch. blood flow; for example, necrosis has been reported in The realization that increasing numbers of both angioglioblastomas and attributed to hypoxia resulting from genic activators and inhibitors are being discovered inadequate vascularization. In turn, this clue led to the (currently, there are at least a dozen of each), most discovery that hypoxia can induce VEGF synthesis with demonstrable activity directly on endothelial cells, (Shweike et al., 1992; Shweiki et al., 1995; Stein et al., raises an interesting question: how are all of these com-1995) . One study in which VEGF receptor function was plementary and opposing signals integrated by the siginhibited in a transplantable glioblastoma with a dominal transduction network in endothelial cells, so as to nant-negative VEGF receptor resulted in impaired tumor control the complex dynamics of maintaining quiesgrowth, which was ascribed to widespread necrotic cell cence, activating angiogenesis, and then completing death (Millauer et al., 1994) . In addition, however, to differentiation to produce functional new capillaries? necrotic cell death, it is now becoming clear that rapid Beyond the manifest goal of further clarifying the regulaexpansion of a tumor mass can be significantly affected tory mechanisms of the angiogenic switch and the comby the incidence of apoptosis. plex process of angiogenesis, an important opportunity To exemplify the interplay of apoptosis and angiogennow exists to apply this new knowledge in clinical oncolesis, consider the transplantable Lewis lung carcinoma ogy to restrict angiogenesis by altering the balance of model ( Figure 5A ). Lewis lung tumors growing subcutaneously in mice seed distant metastases in the lung, but angiogenic regulators. (A) Liver metastases from a subcutaneous growth of Lewis lung carcinoma will grow explosively in the absence (i) of the primary tumor, which produces a circulating endothelial inhibitor (angiostatin). The apoptotic index is low and the proliferation index very high. When the primary tumor is present (ii), resulting in high serum levels of angiostatin, growth of the metastases is impaired, and the apoptotic index is markedly increased in the metastatic nodules. If the primary tumor generating angiostatin is absent, but instead the angiogenesis inhibitory drug AGM1470 (TNP470) is inoculated daily (iii), metastatic growth is again restricted, concomitant with increased apoptosis. Neither angiogenesis inhibitor affects the proliferation index of the metastatic tumor cells (shown); in both cases, the density of new capillaries is significantly reduced (data not shown). (B) Transgenic mice expressing the SV-Tag oncogene in pancreatic ␤ cells develop islet cell carcinomas with a high proliferation index and a low incidence of apoptosis (i). In the absence of the survival factor IGF-II, tumor volume is dramatically impaired, with a concordant 5ϫ increase in apoptotic index (ii), demonstrating that apoptosis can restrain primary tumor growth. When the transgenic mice are treated with a regimen of angiogenesis inhibitors, including AGM1470, tumor growth is again impaired, also with a concordant increase in the incidence of apoptosis (iii), indicating that the reduced vascularization (data not shown) elicits tumor cell apoptosis. Again, tumor cell proliferation is not affected by inhibition of angiogenesis. these remain dormant as small nodules of tumor cells and two additional murine tumors in immunodeficient and syngeneic mice, respectively; tumors in the angiosthat do not elicit angiogenesis, as a consequence of the presence in the blood of high levels of the angiogenesis tatin-treated mice also had comparable proliferation indices to saline-treated controls and markedly increased inhibitor angiostatin, which is released from circulating plasminogen by the primary tumor frequencies of tumor cell apoptosis . In a second example, that of islet cell carcinomas (The reason that angiostatin does not inhibit angiogenesis in the primary tumor is not clear but is thought to in RIP-Tag transgenic mice ( Figure 1A) , the end-stage tumors evidence a low incidence of apoptosis, which reflect a local balance in favor of angiogenesis inducers.) Examination of the latent metastases revealed a high appears to be maintained both by intrinsic factors and by intense vascularization of tumors ( Figure 5B ). When incidence of S-phase cells (30%) and yet little increase in metastatic tumor mass. The explanation appears to the embryonic growth/survival factor IGF-II, which is activated in this tumorigenesis pathway, was abrogated be that the latent metastases evidence a high incidence of apoptosis (8%), balancing rapid cell division with cell using gene-knockout mice, the tumor volume was dramatically decreased (Christofori et al., 1994 (Christofori et al., , 1995a ; Naik death . Release of the angiogenic blockade (by removing the primary tumor) allowed angiet al., 1994) . The S-phase incidence was comparably high (more than 20%) in both normal and IGF-II-deficient ogenesis and rapid expansion of lung metastases O'Reilly et al., 1994) . The synthetic tumors (Naik et al., 1994) ; the difference was in the apoptotic incidence, which rose 5-fold in the IGF-II-null tuangiogenesis inhibitor AGM1470 could similarly hold latent metastases in place; again, the pattern was one of mors (Christofori et al., 1994) . Thus, IGF-II produced by the tumor cells is implicated in the control of apoptosis. high incidence both of cells in S phase and of cells undergoing apoptosis . Recently, Yet the low level of apoptosis seen in the islet cell tumors is also highly dependent on persistent angiogenesis. purified angiostatin has been shown to impair significantly the growth of three primary human carcinomas When the RIP-Tag mice were treated with a regimen of plified both by traditional tumor transplantation models (Teicher et al., 1992) and, more recently, by the use of Christofori, G., Naik, P., and Hanahan, D. (1995a) . Deregulation of both imprinted and expressed alleles of the IGF-II gene during ␤-cell transgenic models of de novo tumorigenesis (Parangi tumorigenesis. Nature Genet. 10, 196-201. et al., 1996) . There is reason to be optimistic that in the Christofori, G., Naik, P., and Hanahan, D. (1995b) . Vascular endotheforeseeable future, the initial angiogenic switch during lial growth factor and its receptors, flt-1 and flk-1, are expressed in tumorigenesis, as well as ongoing neovascularization normal pancreatic islets and throughout islet cell tumorigenesis.
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